Status:
COMPLETED
Effects of Single Oral Dose Dapagliflozin QT Study
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Healthy
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to examine the effect of dapagliflozin on electronic measures of heart beats in healthy males
Eligibility Criteria
Inclusion
- Healthy males age 18 to 45 years of age, who are not currently taking any medications
- Normal screening results including a physical examination, laboratory tests, heart rate, blood pressure, and ECG (electronic measure of the heart)
Exclusion
- No personal or family history of significant heart problems
- No use of over the counter medications within 7 days of the study
- No use of prescription medicaiton within 1 month of the study
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00688493
Start Date
July 1 2007
End Date
April 1 2008
Last Update
March 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Baltimore, Maryland, United States